Triscari J, Swanson B N, Willard D A, Cohen A I, Devault A, Pan H Y
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ.
Br J Clin Pharmacol. 1993 Sep;36(3):263-5. doi: 10.1111/j.1365-2125.1993.tb04227.x.
Pravastatin is an HMG CoA reductase inhibitor used in the treatment of hypercholesterolaemia. The steady state pharmacokinetics of pravastatin (20 mg) and digoxin (0.2 mg) were evaluated in 18 healthy male subjects following the administration of each drug alone or in combination for 9 days. Serum and urine were collected for up to 48 h after the ninth dose in this open, randomized 3-way crossover study. Digoxin concentrations were measured by radioimmunoassay, and pravastatin and its metabolites. SQ 31,906 and SQ 31,945 were measured by GC-MS. Digoxin and pravastatin pharmacokinetics were unchanged following combined administration. Combination therapy with pravastatin and digoxin is unlikely to expose patients to additional risk compared with pravastatin alone.
普伐他汀是一种用于治疗高胆固醇血症的HMG CoA还原酶抑制剂。在18名健康男性受试者中，单独或联合服用每种药物9天后，评估了普伐他汀（20毫克）和地高辛（0.2毫克）的稳态药代动力学。在这项开放、随机的三向交叉研究中，在第九剂给药后长达48小时收集血清和尿液。用地高辛放射免疫分析法测量地高辛浓度，用气相色谱-质谱法测量普伐他汀及其代谢物SQ 31,906和SQ 31,945。联合给药后，地高辛和普伐他汀的药代动力学没有变化。与单独使用普伐他汀相比，普伐他汀和地高辛联合治疗不太可能使患者面临额外风险。
